We are now entering an era where we are learning more about molecular differences and driving mechanisms among pancreatic cancers, with the hope of identifying personalized strategies for patient subsets. For the community oncologist, it’s more important than ever to keep up with the new research and understand the options for clinical trials.
Panelists: John L. Marshall, MD, Georgetown University; George Kim, MD, 21st Century Oncology; Kabir Mody, MD, Mayo Clinic Cancer Center; Eileen M. O’Reilly, M D, Memorial Sloan Kettering Cancer Center; Tanios S. Bekaii-Saab, MD, Mayo Clinic Cancer Center. To learn more Enter Here . . .